Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry

Daniel Perez-Zsolt, Itziar Erkizia, Maria Pino, Mónica García-Gallo, Maria Teresa Martin, Susana Benet, Jakub Chojnacki, María Teresa Fernández-Figueras, Dolores Guerrero, Victor Urrea, Xabier Muñiz-Trabudua, Leonor Kremer, Javier Martinez-Picado, Nuria Izquierdo-Useros

    Research output: Contribution to journalArticleResearch

    26 Citations (Scopus)


    © 2019, The Author(s), under exclusive licence to Springer Nature Limited. Several Ebola viruses cause outbreaks of lethal haemorrhagic fever in humans, but developing therapies tackle only Zaire Ebola virus. Dendritic cells (DCs) are targets of this infection in vivo. Here, we found that Ebola virus entry into activated DCs requires the sialic acid-binding Ig-like lectin 1 (Siglec-1/CD169), which recognizes sialylated gangliosides anchored to viral membranes. Blockage of the Siglec-1 receptor by anti-Siglec-1 monoclonal antibodies halted Ebola viral uptake and cytoplasmic entry, offering cross-protection against other ganglioside-containing viruses such as human immunodeficiency virus type 1.
    Original languageEnglish
    Pages (from-to)1558-1570
    JournalNature Microbiology
    Publication statusPublished - 1 Sep 2019


    Dive into the research topics of 'Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry'. Together they form a unique fingerprint.

    Cite this